Dexamethasone is a synthetic steriod of widespread use in oncology especially for the management of radiation-induced cerebral oedema which accompanies intracranial malignancies.It has been recently suggested that Dexamethasone could modify the severity and incidence of misonidazole (MISO; 1-(2-hydroxy-3-methoxypropyl)-2-nitroimidazole) neurotoxicity (Walker & Strike, 1980; Wasserman et al., 1980; Urtasun et al., 1982) . Prospective clinical studies are underway to assess the efficacy of Dexamethasone when administered concomitantly with radiation and MISO (Urtasun et al., 1982) .
There is, however, recent published in vitro evidence that overnight exposure to microgram quantities of Dexamethasone decreases the sensitivity of Chinese Hamster cells, V-79-753B to radiation both in air and hypoxia (Millar & Jinks, 1981 (Tsuei et al., 1979) The amount of Dexamethasone in the plasma and tumour specimens was determined by a modification of the high pressure liquid chromatography (HPLC) method of Cham et al. (1980) . The procedure was modified in that Dexamethasone was extracted from serum samples or tumour homogenates by means of the SEP PAK solid phase extraction system for steroids (Waters Associates, Inc.). Weighed tumours were homogenized in 1.5ml of distilled water in a Ten Broeck homogenizer, the homogenates centrifuged and the supernatants analyzed for Dexamethasone. The accuracy of the measured levels of Dexamethasone in tumour and serum is estimated to be + 15%.
In the radiation part of the experiment 4 groups of C57/B1 mice bearing Lewis lung tumour in the left gastronemius muscle were used. When the leg diameter reached 8mm (0.25 g of tumour) 12 mice were placed in each of four groups (A to D): Group A having no radiation, no Dexamethasone (Control Group); Group B having Dexamethasone alone; Group C having radiation alone; and Group D having radiation and Dexamethasone.
Fifty pg g -1 body wt of Dexamethasone phosphate was administered i.p. every 8h for 24h (three doses) to Groups B and D; the last dose was given 30min prior to radiation treatment in Group D.
Irradiation (3,500 or 1000cGy (Theratron 60Co)) was given in a single dose to the tumour-bearing legs of mice in Groups C and D. All the mice were irradiated at the same time in a jig constructed to hold 24 unanaesthetized mice. The bodies of the mice were protected from the direct beam of radiation by 10 half-value layer thick lead (11 cm) with the tumour-bearing legs only exposed to the beam. To prevent lung metastases, all mice in groups A to D had prophylactic radiation which consisted of a 1,000 cGy single dose to the lungs given 7 days after the inoculation of the legs with tumour cells.
Measurement of the tumour size in the legs was made every 2 days following tumour cell inoculation up to 23 days after the radiation. Tumour regrowth to 4 times the treatment size was considered the experimental termination point.
The data were analyzed by means of a computer programme which provided the average normalized tumour volume for each group of tumours at each measurement. The derived tumour volumes were used to construct the leg volumes/time curve from which the tumour growth delay in days as a function of radiation dose was derived (Figure 1 ). 10 Gy + dexamethasone (U).
The concentration of Dexamethasone at 30 min after injection was found to reach a level of 23 ±3.5 pgg-' in the tumour and a comparable level in the serum. At 8 h the tumour level was approximately 16pgg-' while the serum level had fallen to 2ygml-'. It is clear that adequate levels of Dexamethasone were present in the Lewis lung tumours at the time of irradiation under the conditions of the radiation experiment. The persistence of Dexamethasone in the tumours of the C57/B1 mice is consistent with the observation that the plasma half-life of Dexamethasone in man is -3h while tissue half-life is much longer ranging from 36-72h (Tsuei et al., 1979; Swartz & Dluhy, 1978) .
The log average tumour volume/time curve (Figure 1) does not show any significant difference in radiation response between the group that had Dexamethasone and the group which was not given the drug (i.e. Groups C and D). Also, no difference was noted in the rate of tumour regrowth in the control group (Group A) and the group given Dexamethasone alone (Group B).
The usual dose of Dexamethasone prescribed in the management of radiation-induced cerebral oedema is in the range of 20mg per day in divided doses. In our series of experiments, 50Mgg'-body wt was given to each mouse (equivalent to 3.5 g for an average man weighing 70 kg). We have found no effect on the response of the Lewis lung tumour to radiation in vivo. Our results are consistent with the finding that Dexamethasone does not change the radiation response of the CFU-S component of bone marrow cells in vivo (Millar & Jinks, 1981) .
On exposure V-79-753B Chinese Hamster cells to the same concentration of Dexamethasone (50pgml-1) over 24h, a considerable increase in Do value was noted both in air and hypoxia (Millar & Jinks, 1981) . This find has raised concerns about the well-established use of Dexamethasone in clinical radiotherapy, particularly in the treatment of CNS tumours. The possible radioprotection of tumour cells is not substantiated in the results obtained with our single mouse tumour model, which should be extended by others using different in vivo tumour model systems. At this time, therefore, we continue to advocate the use of Dexamethasone in combination with radiation when clinically indicated.
